Last Friday, Cosmo Pharmaceuticals shares closed at 91.40 Swiss francs, while the week before it was at 62.20 francs. The reason for the record rise is the company's announcement on Wednesday (3 December) that its product to combat male pattern baldness has performed exceptionally well in advanced phase clinical testing. It would mark the biggest turnaround in the treatment of male androgenic alopecia (baldness) in more than thirty years.
Testing of an external-use solution applied to the scalp, called clascoterone 5% topical solution, has produced "breakthrough" results, the company says. Compared to the placebo solution, the former resulted in a significant increase in hair count (Target-Area Hair Count) of up to 539 percent, while the latter was a 168 percent increase.
Meanwhile, the second group of men had a denser hair growth than the first at the time the test began, which completely explains the percentage difference, according to Cosmo Pharmaceuticals. Thus, in the case of a thinner hair growth, the percentage improvement in thickening is many times more pronounced than in the case of a less thin hair growth.
Nearly 1,500 volunteers participated in both tests, which were conducted in the USA and Europe.
